- Home
- DAWN
as 07-26-2024 4:00pm EST
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 1.2B | IPO Year: | 2021 |
| Target Price: | $38.00 | AVG Volume (30 days): | 995.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.67 - $18.07 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 453.67% |
Stock Insider Trading Activity of Day One Biopharmaceuticals Inc. (DAWN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ramasastry Saira | DAWN | Director | Jun 21 '24 | Sell | $13.19 | 10,000 | $131,877.00 | 40,485 | SEC Form 4 |
| Blackman Samuel C. | DAWN | HEAD OF R&D | Jun 10 '24 | Sell | $12.62 | 30,000 | $378,588.00 | 1,141,081 | SEC Form 4 |
| Blackman Samuel C. | DAWN | HEAD OF R&D | May 15 '24 | Sell | $16.08 | 2,267 | $36,450.41 | 1,171,081 | SEC Form 4 |
| York Charles N II | DAWN | COO, CFO AND SECRETARY | May 15 '24 | Sell | $16.08 | 2,675 | $43,010.52 | 224,868 | SEC Form 4 |
| Dubow Adam | DAWN | GENERAL COUNSEL | May 15 '24 | Sell | $16.08 | 3,253 | $52,304.01 | 21,731 | SEC Form 4 |
| Bender Jeremy | DAWN | CHIEF EXECUTIVE OFFICER | May 15 '24 | Sell | $16.08 | 7,873 | $126,587.61 | 654,728 | SEC Form 4 |
| Blackman Samuel C. | DAWN | HEAD OF R&D | May 10 '24 | Sell | $16.37 | 10,000 | $163,743.00 | 1,164,662 | SEC Form 4 |
| Bender Jeremy | DAWN | CHIEF EXECUTIVE OFFICER | May 1 '24 | Sell | $17.88 | 70,051 | $1,252,182.64 | 651,762 | SEC Form 4 |
| Bender Jeremy | DAWN | CHIEF EXECUTIVE OFFICER | May 1 '24 | Sell | $17.94 | 6 | $107.63 | 651,756 | SEC Form 4 |
| Bender Jeremy | DAWN | CHIEF EXECUTIVE OFFICER | May 1 '24 | Sell | $17.85 | 9,154 | $163,417.21 | 642,602 | SEC Form 4 |
| York Charles N II | DAWN | COO, CFO AND SECRETARY | May 1 '24 | Sell | $17.89 | 52,183 | $933,397.32 | 225,571 | SEC Form 4 |
| York Charles N II | DAWN | COO, CFO AND SECRETARY | May 1 '24 | Sell | $17.90 | 200 | $3,579.10 | 225,371 | SEC Form 4 |
| York Charles N II | DAWN | COO, CFO AND SECRETARY | May 1 '24 | Sell | $17.85 | 8,078 | $144,214.11 | 217,293 | SEC Form 4 |
| Blackman Samuel C. | DAWN | HEAD OF R&D | Apr 18 '24 | Sell | $16.02 | 10,000 | $160,163.00 | 1,174,662 | SEC Form 4 |
| Blackman Samuel C. | DAWN | HEAD OF R&D | Mar 25 '24 | Sell | $16.01 | 10,000 | $160,055.00 | 1,184,662 | SEC Form 4 |
| Blackman Samuel C. | DAWN | HEAD OF R&D | Mar 11 '24 | Sell | $15.24 | 30,000 | $457,314.00 | 1,194,662 | SEC Form 4 |
| Blackman Samuel C. | DAWN | HEAD OF R&D | Feb 27 '24 | Sell | $16.11 | 20,000 | $322,166.00 | 1,224,662 | SEC Form 4 |
| York Charles N II | DAWN | COO, CFO AND SECRETARY | Feb 15 '24 | Sell | $15.25 | 2,666 | $40,651.43 | 277,754 | SEC Form 4 |
| Dubow Adam | DAWN | GENERAL COUNSEL | Feb 15 '24 | Sell | $15.25 | 3,242 | $49,434.34 | 16,585 | SEC Form 4 |
| Blackman Samuel C. | DAWN | HEAD OF RESEARCH AND DEVELOPME | Feb 15 '24 | Sell | $15.25 | 2,258 | $34,430.21 | 1,244,662 | SEC Form 4 |
| Bender Jeremy | DAWN | CHIEF EXECUTIVE OFFICER | Feb 15 '24 | Sell | $15.25 | 7,615 | $116,114.28 | 721,813 | SEC Form 4 |
| Dubow Adam | DAWN | General Counsel | Nov 15 '23 | Sell | $11.69 | 5,313 | $62,108.97 | 11,428 | SEC Form 4 |
| Blackman Samuel C. | DAWN | Head of Research and Developme | Nov 15 '23 | Sell | $11.69 | 709 | $8,288.21 | 1,238,234 | SEC Form 4 |
| Bender Jeremy | DAWN | Chief Executive Officer | Nov 15 '23 | Sell | $11.69 | 3,107 | $36,320.83 | 709,429 | SEC Form 4 |
| York Charles N II | DAWN | COO, CFO and Secretary | Nov 15 '23 | Sell | $11.69 | 956 | $11,175.64 | 270,170 | SEC Form 4 |
Latest Day One Biopharmaceuticals Inc. News
DAWN Breaking Stock News: Dive into DAWN Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
a day ago
Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy
MT Newswires
9 days ago
Day One Biopharmaceuticals Insider Sold Shares Worth $320,226, According to a Recent SEC Filing
WWD
a month ago
Lupita Nyong’o Shimmers in Sequined Off-the-shoulder Prada Jumpsuit and Satin Miniskirt at ‘A Quiet Place: Day One’ Premiere
WWD
a month ago
Lupita Nyong’o Gives Power Suiting a Sensual Spin in Double-breasted Blazer and High-waisted Shorts for ‘A Quiet Place: Day One’ Photo Call
GuruFocus.com
a month ago
Insider Selling: Director Saira Ramasastry Sells Shares of Day One Biopharmaceuticals Inc (DAWN)
Pharmaceutical Technology
a month ago
Day One targets the growing ADC market with MabCare acquisition
Zacks
a month ago
Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up
MT Newswires
a month ago
Day One Biopharmaceuticals Signs Licensing Deal With MabCare for MTX-13; Shares Rise
Compare DAWN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DAWN Day One Biopharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.